-
公开(公告)号：EP4272836A2
公开(公告)日：2023-11-08
申请号：EP23196737.3
申请日：2020-04-27
发明人： DENG, Haibing , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号： A61P35/00
摘要： A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.
-
2.发明公开
公开(公告)号：EP4089091A1
公开(公告)日：2022-11-16
申请号：EP21738611.9
申请日：2021-01-05
发明人： ZHANG, Mingming , ZHAO, Baowei , YANG, Fei , YING, Haiyan , ZHANG, Yongxian , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号： C07D471/04 , A61K31/545 , A61K31/5517 , A61K31/4188 , A61P35/00 , A61P35/02 , A61P37/00 , A61P31/04 , A61P31/06 , A61P31/18 , A61P19/10 , A61P3/06
摘要： A biphenyl fluorine double bond derivative having a structure as represented by formula (I), a preparation method therefor, and a pharmaceutical application thereof. The biphenyl fluorine double bond derivative having the structure as represented by formula (I) can be widely applied in the preparation of medicaments for preventing and/or treating cancers or tumors, immune-related diseases and disorders, communicable diseases, infectious diseases or metabolic diseases mediated by PD-1/PD-L1 signal pathways, and is expected to be developed into a new generation of PD-1/PD-L1 inhibitors.
-
3.发明公开
公开(公告)号：EP3632906A1
公开(公告)日：2020-04-08
申请号：EP18805287.2
申请日：2018-05-22
发明人： ZHAO, Baowei , ZHANG, Mingming , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号： C07D401/14 , A61K31/4375
摘要： An azaaryl derivative with the structure of formula (I), a preparation method therefor and a pharmaceutical use thereof are disclosed in the present invention. The series of compounds of the present invention can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary site tumor metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.
-
公开(公告)号：EP4442680A1
公开(公告)日：2024-10-09
申请号：EP22900244.9
申请日：2022-11-09
发明人： DENG, Haibing , YANG, Fei , ZHU, Wei , LIU, Xiaofeng , LIU, Jian , LI, Mingfeng , LIU, Zhaomin , YING, Haiyan , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号： C07D237/32 , C07D401/14 , C07D401/04 , C07D471/14 , C07D471/04 , C07D487/04 , C07D498/04 , A61K31/502 , A61K31/517 , A61K31/519 , A61P35/00
CPC分类号： A61K31/502 , A61K31/517 , A61K31/519 , A61P35/00 , C07D237/32 , C07D401/04 , C07D401/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D498/04
摘要： A pyrazole derivative, and a preparation method therefor and a use thereof in medicine. In particular, the present invention relates to a PRMT5 inhibitor having a structure shown in formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use thereof as a PRMT5 inhibitor, and a use thereof in treatment and/or prevention of a PRMT5-mediated disease.
-
5.发明公开
公开(公告)号：EP4001274A1
公开(公告)日：2022-05-25
申请号：EP20840778.3
申请日：2020-07-13
发明人： YANG, Fei , ZHANG, Yongxian , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号： C07D407/10 , C07D401/14 , C07D401/12 , C07D405/14 , C07D413/14 , C07D213/56 , A61K31/44 , A61K31/4545 , A61K31/444 , A61P35/00 , A61P37/02
摘要： Biphenyl derivatives having a structure of formula (I) and capable of blocking PD-1/PD-L1 interaction, a preparation method therefor and use thereof. The series of compounds can be widely used in the preparation of medicaments for preventing and/or treating cancers or tumors, immune-related disease and disorders, communicable diseases, infectious diseases or metabolic diseases mediated by PD-1/PD-L1 signal pathways, and are expected to be developed into a new generation of PD-1/PD-L1 inhibitors.
-
6.发明公开
公开(公告)号：EP3915977A1
公开(公告)日：2021-12-01
申请号：EP19910981.0
申请日：2019-09-12
发明人： ZHAO, Baowei , XUN, Guoliang , ZHAO, Yuan , FENG, Tao , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号： C07D241/44 , A61K31/498 , A61P35/00
摘要： A 1,2,3,4-tetrahydroquinoxaline derivative having a structure as represented by formula (I), preparation method therefor and application thereof, and the definition on substituents is as stated in the description and the claims. Compounds in the present invention can be widely applied to preparation of drugs for treating one or more tumors, cancers, metabolic diseases, autoimmune diseases or disorders, and a new generation of RORyt agonist drugs is expected to be developed.
-
公开(公告)号：EP4450499A1
公开(公告)日：2024-10-23
申请号：EP22906521.4
申请日：2022-12-12
发明人： ZHANG, Lei , HOU, Qiwen , YU, Hongping
IPC分类号： C07D471/04 , A61K31/519 , A61P35/00
摘要： The present invention relates to an FGFR4 inhibitor acid salt, a preparation method therefor, and a use thereof. The FGFR4 inhibitor is a compound N -((35,45)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4- d ]pyrimidin-2-yl)amino)tetrahydro-2 H -pyran-4-yl)acrylamide having the structure represented by formula (I), and the acid salt is p -toluenesulfonate. The physical and chemical properties such as the solubility and bioavailability of the compound represented by formula (I) in the free form are greatly increased, and the development requirements of clinical medicine preparations can be met. The present invention has vital clinical application value for p-toluenesulfonate and has the prospect of developing into a new generation of FGFR4 small-molecule inhibitors.
-
8.发明公开
公开(公告)号：EP4382511A1
公开(公告)日：2024-06-12
申请号：EP22852217.3
申请日：2022-08-03
发明人： FENG, Tao , ZHAO, Baowei , ZHANG, Mingming , YANG, Shuqun , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号： C07D209/04 , C07D471/04 , A61K31/136 , A61K31/167 , A61K31/404 , A61P35/00
CPC分类号： A61K31/136 , A61K31/167 , A61K31/404 , A61P35/00 , C07D209/04 , C07D471/04
摘要： A pyrimidine or pyridine derivative having a structure represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use thereof as an EGFR inhibitor, and a use thereof in the preparation of a drug for treating and/or preventing cancer, tumors, or metastatic diseases associated at least in part with EGFR exon 20 insertions, deletions, or other mutations, especially a use thereof in the preparation of a drug for treating and/or preventing hyperproliferative diseases and the induction of cell death disorders.
-
9.发明公开
公开(公告)号：EP4257584A1
公开(公告)日：2023-10-11
申请号：EP21900025.4
申请日：2021-12-01
发明人： ZHAO, Baowei , ZHANG, Mingming , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号： C07D401/04 , C07D471/04 , C07D487/04 , C07D403/04 , A61K31/506 , A61P35/00
摘要： The present invention relates to a 2,3-dihydro-1H-pyrrolo[3,2-b]pyridine derivative, a preparation method therefor, and an application thereof, and in particular to an EGFR inhibitor having the structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use of same as an EGFR inhibitor, and a use of same in the treatment and/or prevention of cancers, tumors, or metastatic diseases at least partially related to EGFR exon 20 insertion or deletion mutations, especially a use in the treatment of hyperproliferative diseases and dysfunction in cell death induction. The definition of each substituent in formula (I) is the same as that in the description.
-
公开(公告)号：EP3964518A1
公开(公告)日：2022-03-09
申请号：EP20798596.1
申请日：2020-04-27
发明人： DENG, Haibing , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号： C07H19/16 , C07H19/20 , C07H19/207 , A61K31/70 , A61K31/7052 , A61K31/7076 , A61P35/00
摘要： A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.013 秒)
